Calaspargase Pegol

DRUG16 trials

Sponsors

Children's Oncology Group, St. Jude Children's Research Hospital, New York Medical College, National Cancer Institute (NCI), Andrew E. Place, MD

Conditions

Acute Leukemia of Ambiguous LineageAcute Leukemia of Ambiguous Lineage in RelapseAcute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia With Failed RemissionAcute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic LymphomaB Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

Early Phase 1

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

RecruitingNCT03719105

New York Medical CollegeNK-Cell Leukemia, NK-Cell Lymphoma, Peripheral T Cell Lymphoma

Start: 2019-03-01End: 2028-12-31Target: 40Updated: 2025-08-08

Phase 1

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Active, not recruitingNCT05192889

St. Jude Children's Research HospitalRefractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia

Start: 2022-08-25End: 2027-02-28Updated: 2025-09-22

Venetoclax Basket Trial for High Risk Hematologic Malignancies

RecruitingNCT05292664

Andrew E. Place, MDAcute Leukemia of Ambiguous Lineage, Acute Leukemia of Ambiguous Lineage in Relapse, Acute Lymphoblastic Leukemia, in Relapse +8

Start: 2023-03-29End: 2030-07-02Target: 30Updated: 2026-03-12

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

RecruitingNCT05581030

H. Lee Moffitt Cancer Center and Research InstituteAcute Lymphoblastic Leukemia

Start: 2023-05-01End: 2026-10-01Target: 7Updated: 2026-03-06

Phase 2

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

RecruitingNCT02981628

Children's Oncology GroupRecurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia +1

Start: 2017-06-19End: 2026-12-31Target: 80Updated: 2026-02-23

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Active, not recruitingNCT03117751

St. Jude Children's Research HospitalAcute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma

Start: 2017-03-29End: 2028-09-30Updated: 2025-12-05

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

RecruitingNCT04546399

National Cancer Institute (NCI)Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia

Start: 2020-12-17End: 2028-06-30Target: 461Updated: 2025-09-10

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Active, not recruitingNCT05761171

Children's Oncology GroupRecurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage +9

Start: 2024-01-08End: 2027-12-31Target: 78Updated: 2026-03-31

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

RecruitingNCT06124157

National Cancer Institute (NCI)B Acute Lymphoblastic Leukemia

Start: 2025-05-30End: 2030-12-01Target: 222Updated: 2026-04-03

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

WithdrawnNCT06210750

National Cancer Institute (NCI)T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma

Start: 2024-08-09End: 2026-09-22Updated: 2024-05-17

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

RecruitingNCT06317662

National Cancer Institute (NCI)Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia

Start: 2025-06-05End: 2028-12-31Target: 153Updated: 2026-04-03

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

RecruitingNCT06390319

St. Jude Children's Research HospitalMixed Phenotype Acute Leukemia, T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma

Start: 2024-12-27End: 2033-12-01Target: 100Updated: 2026-02-27

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Not yet recruitingNCT07072585

Children's Oncology GroupStage III T Lymphoblastic Leukemia/Lymphoma, Stage II T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma +2

Start: 2026-06-28End: 2035-09-01Target: 1708Updated: 2025-12-31

Phase 3

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Active, not recruitingNCT03007147

Children's Oncology GroupAcute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia +1

Start: 2017-08-08End: 2027-09-30Target: 475Updated: 2026-02-23

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

RecruitingNCT03959085

Children's Oncology GroupB Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia +2

Start: 2019-10-31End: 2032-03-31Target: 5951Updated: 2026-03-31

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

RecruitingNCT05602194

Children's Oncology GroupB Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 +3

Start: 2023-08-14End: 2028-12-30Target: 440Updated: 2026-03-12

Related Papers

Systemic Epstein–Barr Virus–Positive T‐Cell Lymphoma of Childhood: A Case Series

Pediatric Blood & Cancer2026-03-25

A phase I study of venetoclax in combination with multiagent cytotoxic chemotherapy for children and adolescents with relapsed or refractory acute lymphoblastic leukemia or mixed phenotype acute leukemia: Results of the dose determination cohort

Blood2025-11-03

Increased incidence of delayed methotrexate elimination in pediatric patients with Philadelphia-chromosome positive (Ph+) or ABL-class fusion positive (ABL-Class) acute lymphoblastic leukemia treated with imatinib: Results of a retrospective cohort study by the italian association of pediatric hematology-oncology (AIEOP)

Blood2025-11-03

Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes

Blood2024-11-053 citations

PAX5 Loss Compromises CD22 Protein Levels and Responses to Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Blood2024-11-05

COVID-19 in Pediatric Patients With Acute Lymphoblastic Leukemia or Lymphoma

JAMA Network Open2024-02-1611 citations

"Sandwich" protocol based on modified SMILE regimen for children with newly extranodal NK/T cell lymphoma, nasal type: a single-arm, single-center clinical study.

2023-07-241 citations

A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: Second safety phase results from Children’s Oncology Group AALL1732.

Journal of Clinical Oncology2023-06-0119 citations

Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia.

2022-12-0112 citations

Improving Infectious Adverse Event Reporting in Pediatric ALL

Oncology Times2022-11-15

Pilot Study Using Induction Chemo-Immunotherapy Followed By Consolidation with Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplant in Advanced Stage Mature Non-Anaplastic T- or NK-Cell Lymphoma/Leukemia in Children, Adolescent, and Young Adults

Blood2022-11-15

Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations.

2022-06-0283 citations

CD22 low/Bcl-2 high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia

Blood2021-11-054 citations

Evaluation of CD22 modulation as a mechanism of resistance to inotuzumab ozogamicin (InO): Results from central CD22 testing on the Children’s Oncology Group (COG) phase II trial of INO in children and young adults with CD22+ B-acute lymphoblastic leukemia (B-ALL).

Journal of Clinical Oncology2020-05-2011 citations

Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols

Haematologica2019-10-1056 citations

Immunotherapies for Pediatric B-Cell Acute Lymphoblastic Leukemia Patients

Oncology Times2019-04-25